Navigation Links
Dendreon Announces MEDCAC Panel Reviewed PROVENGE Evidence
Date:11/17/2010

SEATTLE, Nov. 17, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) reviewed the impact of labeled and unlabeled use of PROVENGE® (sipuleucel-T) treatment on health outcomes of patients with advanced prostate cancer. This panel was convened as a part of the National Coverage Analysis (NCA) that was initiated by the Centers for Medicare and Medicaid Services (CMS).  

"PROVENGE is an important new treatment for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer.  "We look forward to working closely with CMS throughout the NCA process to ensure patients with advanced prostate cancer have access to PROVENGE."

PROVENGE is the first in a new therapeutic class known as autologous cellular immunotherapies and is indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.  On June 30, 2010, CMS initiated the NCA of PROVENGE. According to CMS, a draft guidance memo will be issued by March 30, 2011, and the expected NCA completion date is June 30, 2011.

The NCA does not impact existing coverage decisions, nor does it restrict local Medicare Administrative Contractors (MACs) from covering PROVENGE. Therefore, Medicare beneficiaries are able to access PROVENGE, and private payers are also able to cover PROVENGE throughout the NCA process. Currently, MACs covering 14 of the 15 regional territories have established coverage guidelines and/or provided customers with written or verbal guidance on coverage.

PROVENGE Safety

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
2. Dendreon to Host Conference Call on November 3rd to Announce Third Quarter Financial Results
3. Dendreon Announces Change in Board of Directors
4. Dendreon Announces Election of Dr. David C. Stump to Board of Directors
5. Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
6. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
7. Dendreon Announces Pricing of Common Stock Offering
8. Dendreon Appoints Hans Bishop as Chief Operating Officer
9. Dendreon Announces Proposed Public Offering of Common Stock
10. Dendreon Receives FDA Acknowledgement of Complete Response
11. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient ... its myPROpad™ ePRO tablet with the addition of a ... most widely used and well-respected Patient Reported Outcome (PRO) ... is used during clinical trials and in other health ... used to demonstrate Health-Related Quality of Life outcomes (HRQoL) ...
(Date:8/19/2014)... Columbia, Md. (PRWEB) August 19, 2014 ... integrated liquid chromatography systems, Prominence-i and Nexera-i, adding ... UHPLC systems. Combining excellent functionality, an intuitive operating ... performance and a more efficient workflow for conventional ... systems feature innovative, intuitive and intelligent design so ...
(Date:8/19/2014)... Calif. (PRWEB) August 19, 2014 ... campaign to raise $200,000 to fund a corporate ... device. , This development is a critical ... model of care to the implementation of personalized ... method of practicing medicine. , Indiegogo contributions will ...
(Date:8/19/2014)... XenoTech announces an exclusive partnership ... production from bioactive small molecules. Based on ... enables convenient and timely assessment of critical metabolite ... President of Commercial Operations, Christian Darabant, “the value ... can be measured directly by comparison with the ...
Breaking Biology Technology:EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 2Beyond Metabolite Identification, Testable Quantities Now Offered by XenoTech 3
... approach to developing anti-infective medicines provides hope ... for combating problems of ... 8 Anacor,Pharmaceuticals and GlaxoSmithKline today announced that they ... development and,commercialization of novel medicines for viral and bacterial ...
... (Amex: ANX ), a biopharmaceutical research and ... the treatment,of cancer and infectious diseases, announced today ... position of vice president of commercialization. Mr.,Erwin will ... commercial operations. "We are pleased to have ...
... Cleanup and rebuilding teams responding to the devastation across ... help from space. A series of crisis map products ... provided to aid damage assessment efforts following the activation ... , More than 60 people were killed and thousands ...
Cached Biology Technology:GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 2GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 3GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 4GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry 5ADVENTRX Appoints Vice President of Commercialization 2ADVENTRX Appoints Vice President of Commercialization 3Greeks get space-based help in wake of deadly fires 2
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... In many parts of the world, leprosy and ... new cases of leprosy per year, with nearly ... The currently available century-old vaccine Bacille Calmette-Guerin, or ... and leprosy, so a more potent vaccine is ... have found a stronger weapon against both diseases., ...
(Date:8/19/2014)... ) -- Scientists at the Houston Methodist Research Institute ... single cells using a pipette -- a common laboratory ... feat and preliminary test results in a recent issue ... . , "Studying single cells and their unique functions ... nanomedicine department. faculty member Lidong Qin, Ph.D., the project,s ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2
... A potential new energy source so controversial that people ... acceptance by the mainstream scientific community. That,s the conclusion of ... the topic "cold fusion" being held here for ... 239th National Meeting of the American Chemical Society (ACS). ...
... release is available in Spanish . , Feeding ... of their regular diet makes them less aggressive and easier ... (ARS) scientists and cooperators. The tryptophan-enhanced diet reduced aggression ... 8-month study. Tryptophan, which is only acquired through diet, is ...
... Michael M. Graham, Ph.D., M.D., president, SNM, Robert W. ... Isotope Task Force, Jeffrey P. Norenberg, Pharm.D., M.S., SNM ... Isotope Task Force, WHEN:,Immediately WHAT:,Discuss the ... period when cancer, heart and brain disease patients will ...
Cached Biology News:'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4Tryptophan-enriched diet reduces pig aggression 2
... software, PC, is used to perform ... obtained from the Experion automated electrophoresis ... electropherogram and simulated gel views and ... in a Results table. This software ...
... use in the Microsart e.motion are sterile-sealed, without ... a specially designed individual package on a band. ... of membrane filter units ensures that they are ... sealed band guarantees uniform dispensing of the individual ...
... that will help protect your PCR runs ... work area prior to use, reducing the ... Containment features reduce the chance of airborne ... for a clear view, an acid-resistant black ...
...
Biology Products: